Issuances of Securities (Details Narrative) - USD ($)		1 Months Ended	12 Months Ended
Issuances of Securities (Details Narrative) - USD ($)	Sep. 01, 2022	Jun. 20, 2024	Dec. 31, 2024	Dec. 31, 2023	Jun. 26, 2024
Unrecognized compensation cost			$ 24,938,630
Common stock issued for litigation settlement				1,850,000
Common stock purchase agreement description	On September 1, 2022, the Company entered into a common stock purchase agreement (the “CSPA”) with White Lion Capital, LLC (“White Lion”). Pursuant to the CSPA, the Company has the right, but not the obligation, to require White Lion to purchase up to $10,000,000 of the Company’s common stock, subject to certain limitations and conditions set forth in the CSPA. The Company is required to register the resale of the shares issuable to White Lion under the CSPA with the U.S. Securities and Exchange Commission, as a condition to requesting White Lion purchase shares. On September 7, 2022, the Company filed a registration statement on Form S-3 to register for resale up to 15,000,000 common shares. The Company’s S-3 registration statement was declared effective by the SEC on September 19, 2022	On June 20, 2024, the Company and White Lion amended the CSPA (the “Second Amendment”) to provide that the purchase price to be paid by White Lion for shares of the Company’s common stock pursuant to the CSPA equals the lower of: (i) 93% of the volume-weighted average price of the Company’s common stock during a period of five consecutive trading days following the Company’s exercise of its right to sell shares (or 95% of that volume-weighted average price if the Company’s common stock is trading on a national exchange), or (ii) the closing price of the common stock on the day the Company exercises its right to sell shares, subject to a floor price of $0.25 per share. The Second Amendment further provides that if the Company issues a share price purchase notice at a time that the Company’s common stock is trading below the floor price and White Lion waives the floor price condition, the purchase price to be paid by White Lion for such shares shall equal 90% multiplied
Stock issued for litigation settlement				$ 462,500
Proceeds from sale of common stock			$ 66,000	$ 0
Common stock, shares issued			252,408,222	244,783,222
Loss on settlement of debt			$ 115,085	$ (80,532)
Common Stocks [Member]
Sale of common stock, shares			825,000
Proceeds from sale of common stock			$ 66,000
Common stock, shares issued			825,000
Warrants issued			412,500
Proceeds allocated to common stock			$ 60,010
Proceeds allocated to warrants			$ 5,990
Officers And Management [Member]
Issuance of common stock for services, shares				1,204,688
Fair value of common stock				$ 271,031
Accrued liabilities				218,250
Loss on settlement of debt				$ (52,781)
Consultants [Member]
Issuance of common stock for services, shares				712,500
Fair value of common stock				$ 153,751
Accrued liabilities				126,000
Loss on settlement of debt				$ (27,751)
Non Affiliated Investor [Member] \| Private Placement [Member]
Sale of common stock, shares			5,300,000	10,145,000
Proceeds from sale of common stock			$ 852,179	$ 2,308,674
Subscription receivable				50,550
Legal and administrative fees			$ 11,400	$ 17,400
Warrants [Member]
Warrants sale of units			825,000
Proceeds allocated to warrants			$ 5,990
Aggregate intrinsic value			$ 0
Issued warrants related to the sale of units			412,500
Restricted Stock Units [Member]
Resale of additional shares					1,500,000
Restricted stock units (RSU) outstanding			46,165,000	47,665,000
Number of restricted stock units (RSU) vested			1,500,000
Stock-based compensation expense			$ 375,000

United Health Products, Inc. 10-K